🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

212 results for “Bristol-Myers” Clear

  1. A study to investigate immune challenge induced skin reactions with SAR445399, canakinumab and spesolimab compared with placebo, in healthy participants aged 18 to 55 years

    Sanofi Pharma Bristol-Myers Squibb

    Immuun system diseases

    phase 1 other active

    1 trial

  2. A study to investigate the bioavailability of the SAR444656 test formulation and the food effect on the SAR444656 test formulation in healthy adult participants

    Sanofi Pharma Bristol-Myers Squibb

    Healthy Volunteer

    phase 1 other active

    1 trial

  3. A study to investigate the pharmacokinetics and safety of a single dose of duvakitug in healthy adult participants

    Sanofi Pharma Bristol-Myers Squibb

    Healthy Volunteers

    phase 1 other active

    1 trial

  4. A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma

    Sanofi Pharma Bristol-Myers Squibb

    Plasma cell myeloma refractory

    phase 1 other active

    1 trial

  5. A study to test a medicine (fitusiran) for preventing bleeds in people with severe hemophilia who previously received preventive treatment with emicizumab

    Sanofi Pharma Bristol-Myers Squibb

    Hemophilia A

    phase 1 other active

    1 trial

  6. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fasting condition.

    Pharma Mar S.A.

    plaque psoriasis

    phase 1 other active

    1 trial

  7. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fed condition

    Pharma Mar S.A.

    plaque psoriasis

    phase 1 other active

    1 trial

  8. An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 1 other active

    1 trial

  9. Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 1 other active

    1 trial

  10. Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus

    Bristol-Myers Squibb / Pfizer EEIG

    Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  11. Phase 1 study on SAR443122 bioavailability and food effect in healthy adults

    Sanofi Pharma Bristol-Myers Squibb

    Colitis ulcerative

    phase 1 other active

    1 trial

  12. SAR447971 first-in-human study

    Sanofi Pharma Bristol-Myers Squibb

    Hidradenitis

    phase 1 other active

    1 trial

  13. Safety and tolerability of single and multiple ascending doses of lunsekimig (SAR443765) in healthy participants

    Sanofi Pharma Bristol-Myers Squibb

    Asthma

    phase 1 other active

    1 trial

  14. Single-center, single-dose, open-label, laboratory-blinded, randomized, two-treatment, two-period bioequivalence (BE) study comparing the Test Product Apixaban 5 mg film-coated tablets (MEDITOP) with the Reference Product Eliquis 5 mg film-coated tablets (Bristol-Myers Squibb/Pfizer) under fasting conditions.

    Pari Pharma GmbH

    Comparative bioequivalence study in healthy volunteers under fasting conditions.

    phase 1 other active

    1 trial

  15. Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

    Bristol-Myers Squibb / Pfizer EEIG

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  16. [14C]-BMS986504 Mass Balance Study in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  17. Dupilumab, dupilumab placebo, solution for injection in pre-filled syringe

    Sanofi Pharma Bristol-Myers Squibb

    Asthma

    approved small molecule active

    1 trial

  18. Dupilumab, matched placebo for test product, Ventolin Evohaler 100 micrograms

    Sanofi Pharma Bristol-Myers Squibb

    Respiratory tract diseases

    approved small molecule active

    1 trial

  19. INSULIN GLARGINE

    Sanofi Pharma Bristol-Myers Squibb

    Diabetes mellitus II

    approved small molecule active

    1 trial

  20. USTEKINUMAB, USTEKINUMAB, deucravacitinib

    Bristol-Myers Squibb / Pfizer EEIG

    Moderate to Severe Plaque Psoriasis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources